STOCK TITAN

David Rodman sells multiple Mineralys (NASDAQ: MLYS) share tranches in Q1 2026

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
144

Rhea-AI Filing Summary

Mineralys Therapeutics reports multiple sales of Common Stock by David Rodman. The filings list a series of dispositions between 01/02/2026 and 03/12/2026, including transfers of 192,715 shares on 01/05/2026 and smaller tranches through March.

Transactions are characterized as cash or broker‑assisted cashless exercises and list per‑trade share counts and proceeds, indicating routine insider dispositions over the stated period.

Positive

  • None.

Negative

  • None.

Insights

Series of scheduled insider dispositions by a single reporting person over two months.

The record shows repeated sales by David Rodman from 01/02/2026 through 03/12/2026, with a large block of 192,715 shares on 01/05/2026. The entries list gross proceeds per trade, indicating executed dispositions rather than grants.

These appear as routine liquidity events; cashflow recipients are the selling holder(s). Subsequent filings would be required to see aggregated impact on beneficial ownership.

Transactions include both cash and broker‑assisted cashless exercises tied to option exercises.

The excerpt shows exercises dated 03/12/2026 and 03/12/2025 with listed share counts 7,709 and 6,349, respectively, described as "Broker assisted cashless exercise" and "Cash." These labels identify the settlement method for option exercises.

Such mixed settlement methods are common for option liquidity; the filing does not state tax treatment or remaining option positions.

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

FAQ

What insider transactions does MLYS disclose in this Form 144?

The Form 144 records multiple dispositions by David Rodman between 01/02/2026 and 03/12/2026. Notable entries include a sale of 192,715 shares on 01/05/2026 and several smaller tranches across January–March.

Were any option exercises reported in the MLYS excerpt?

Yes. The excerpt lists option exercises on 03/12/2026 described as a "Broker assisted cashless exercise" for 7,709 shares and a 03/12/2025 "Cash" exercise for 6,349 shares, showing mixed settlement methods.

How are proceeds shown for the reported transactions in the MLYS filing?

Each trade line includes gross proceeds figures for the selling transactions, for example 6,749,100.06 associated with 192,715 shares on 01/05/2026. The entries list per‑trade proceeds alongside share counts.

Does the Form 144 excerpt show a change in beneficial ownership for MLYS?

The excerpt lists multiple sales by a reporting person but does not state aggregate post‑transaction beneficial ownership totals. It documents per‑trade dispositions and proceeds without summarizing remaining holdings or percentage ownership.
Mineralys Therapeutics, Inc.

NASDAQ:MLYS

View MLYS Stock Overview

MLYS Rankings

MLYS Latest News

MLYS Latest SEC Filings

MLYS Stock Data

2.14B
75.18M
Biotechnology
Pharmaceutical Preparations
Link
United States
RADNOR